The event was well attended, reflecting strong engagement from the financial community as Xanadu advances toward becoming a publicly listed company.

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 ...

JD.com, Inc. (NASDAQ: JD and HKEX: 9618 (HKD counter) and 89618 (RMB counter), the "Company" or "JD.com"), a leading supply chain-based technology and service ...

In advanced semiconductor manufacturing, inspection and FA are not overhead—they are economic control mechanisms that protect ...